Cosentyx My Path Forward

Track your moderate to severe psoriasis progress in a completely different way.

The COSENTYX® (secukinumab) MY PATH FORWARD app from Novartis Pharmaceuticals Corporation lets you track your journey with COSENTYX.

PLEASE NOTE: COSENTYX My Path Forward will no longer be offered in the App Store after 12/2020.

Install the FREE top-ranked PILL REMINDER & MEDICATION TRACKER – MEDISAFE app today for continued support and content for your COSENTYX treatment. MEDISAFE supports patients treating plaque psoriasis, active psoriatic arthritis or active ankylosing spondylitis.

With MEDISAFE, you can access COSENTYX information, set reminders for injections and refills, and more! MEDISAFE also allows you to manage other medications you take.

This app is not a medical device and does not take the place of advice from your doctor.

INDICATIONS: COSENTYX® (secukinumab) is a prescription medicine used to treat adults: with active psoriatic arthritis; with moderate to severe plaque psoriasis that involves large areas or many areas of the body, and who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using UV light, alone or with systemic therapy); with active ankylosing spondylitis.

IMPORTANT SAFETY INFORMATION: Do not use COSENTYX if you have had a severe allergic reaction to secukinumab or any of the other ingredients in COSENTYX. See the Medication Guide for a complete list of ingredients.

COSENTYX is a medicine that affects your immune system. COSENTYX may increase your risk of having serious side effects such as:

Infections: COSENTYX may lower the ability of your immune system to fight infections and may increase your risk of infections. Your doctor should check you for tuberculosis (TB) before starting treatment with COSENTYX. If your doctor feels that you are at risk for TB, you may be treated with medicine for TB before you begin treatment with COSENTYX and during treatment with COSENTYX. Your doctor should watch you closely for signs and symptoms of TB during treatment with COSENTYX. Do not take COSENTYX if you have an active TB infection.

Before starting COSENTYX, tell your doctor if you: are being treated for an infection, have an infection that does not go away or that keeps coming back, have TB or have been in close contact with someone with TB, think you have an infection or have symptoms of an infection such as: fevers, sweats, or chills; muscle aches; cough; shortness of breath; blood in your phlegm; weight loss; warm, red, or painful skin or sores on your body; diarrhea or stomach pain; burning when you urinate or urinate more often than normal.

After starting COSENTYX, call your doctor right away if you have any signs of infection listed above.

Do not use COSENTYX if you have any signs of infection unless you are instructed to by your doctor.

Inflammatory Bowel Disease: New cases of inflammatory bowel disease or “flare-ups” can happen

with COSENTYX, and can sometimes be serious. If you have inflammatory bowel disease (ulcerative colitis or Crohn’s disease), tell your doctor if you have worsening disease symptoms during treatment with COSENTYX or develop new symptoms of stomach pain or diarrhea.

Serious Allergic Reactions: Serious allergic reactions can occur. Get emergency medical help right away

if you get any of the following symptoms: feeling faint; swelling of your face, eyelids, lips, mouth, tongue, or throat; trouble breathing or throat tightness; chest tightness; or skin rash. If you have a severe allergic reaction, do not give another injection of COSENTYX.

The most common side effects of COSENTYX include: cold symptoms, diarrhea, and upper respiratory infections. These are not all of the possible side effects of COSENTYX. Call your doctor for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see Prescribing Information at https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/cosentyx.pdf